Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis

British Journal of Pharmacology

Volumn 176, Issue 10, 2019, Pages 1585-1600

  Espejo Porras, Francisco ^a,b,c   García Toscano, Laura ^a,b,c   Rodríguez Cueto, Carmen ^a,b,c   Santos García, Irene ^a,b,c   de Lago, Eva ^a,b,c   Fernandez Ruiz, Javier ^a,b,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; CANNABINOID 2 RECEPTOR; CELL PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; IBA 1 PROTEIN; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; BENZOXAZINE DERIVATIVE; CANNABINOID; CANNABINOID RECEPTOR AGONIST; DNA BINDING PROTEIN; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; TDP-43 PROTEIN, MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BODY WEIGHT LOSS; CELL ACTIVATION; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; GLIOSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MICROGLIA; MOTONEURON; MOUSE; NISSL STAINING; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; ROTAROD TEST; UPREGULATION; ANIMAL; DISEASE MODEL; GENETICS; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BENZOXAZINES; CANNABINOID RECEPTOR AGONISTS; CANNABINOIDS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; MICE, TRANSGENIC; MICROGLIA; MORPHOLINES; MOTOR ACTIVITY; MOTOR NEURONS; NAPHTHALENES; RECEPTOR, CANNABINOID, CB2; ROTAROD PERFORMANCE TEST;

EID: 85046481050     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.14216     Document Type: Article

References (50)

1. Al-Chalabi A, Hardiman O (2013). The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 9: 617–628.
2. Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA et al. (2017a). The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. Br J Pharmacol 174: S17–S129.
3. Alexander SPH, Cidlowski JA, Kelly E, Marrion NV, Peters JA, Faccenda E et al. (2017b). The Concise Guide to PHARMACOLOGY 2017/18: Nuclear hormone receptors. Br J Pharmacol 174: S208–S224.
4. Alexander SPH, Fabbro D, Kelly E, Marrion NV, Peters JA, Faccenda E et al. (2017c). The Concise Guide to PHARMACOLOGY 2017/18: Enzymes. Br J Pharmacol 174: S272–S359.
5. Alexander SPH, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD et al. (2017d). The Concise Guide to PHARMACOLOGY 2017/18: Transporters. Br J Pharmacol 174: S360–S446.
6. Alvarez FJ, Lafuente H, Rey-Santano MC, Mielgo VE, Gastiasoro E, Rueda M et al. (2008). Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr Res 64: 653–658.
7. Bilsland LG, Dick JR, Pryce G, Petrosino S, Di Marzo V, Baker D et al. (2006). Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J 20: 1003–1005.
8. Bova MP, Kinney GG (2013). Emerging drug targets in amyotrophic lateral sclerosis. Expert Opin Orphan Drugs 1: 5–20.
9. Buratti E, Baralle FE (2010). The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. RNA Biol 7: 420–429.
10. Ceprián M, Jiménez-Sánchez L, Vargas C, Barata L, Hind W, Martínez-Orgado J (2017). Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke. Neuropharmacology 116: 151–159.
11. Cruts M, Gijselinck I, Van Langenhove T, van der Zee J, Van Broeckhoven C (2013). Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci 36: 450–459.
12. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.
13. de Lago E, Moreno-Martet M, Cabranes A, Ramos JA, Fernández-Ruiz J (2012). Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology 62: 2299–2308.
14. de Lago E, Moreno-Martet M, Espejo-Porras F, Fernández-Ruiz J (2015). Endocannabinoids and amyotrophic lateral sclerosis. In: Fattore L (ed). Cannabinoids in Neurologic and Mental Disease. Elsevier: The Netherlands, pp. 99–124.
15. Diaz E, Morales H (2016). Spinal cord anatomy and clinical syndromes. Semin Ultrasound CT MR 37: 360–371.
16. Esmaeili MA, Panahi M, Yadav S, Hennings L, Kiaei M (2013). Premature death of TDP-43 (A315T) transgenic mice due to gastrointestinal complications prior to development of full neurological symptoms of amyotrophic lateral sclerosis. Int J Exp Pathol 94: 56–64.
17. Espejo-Porras F, Piscitelli F, Verde R, Ramos JA, Di Marzo V, de Lago E et al. (2015). Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders. J Neuroimmune Pharmacol 10: 233–244.
18. Fernández-Ruiz J, Romero J, Velasco G, Tolón RM, Ramos JA, Guzmán M (2007). Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci 28: 39–45.
19. Fernández-Ruiz J, Moro MA, Martínez-Orgado J (2015). Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications. Neurotherapeutics 12: 793–806.
20. Fernández-Trapero M, Espejo-Porras F, Rodríguez-Cueto C, Coates JR, Pérez-Díaz C, de Lago E et al. (2017). Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. Dis Model Mech 10: 551–558.
21. Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ (2011). Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol 7: 616–630.
22. Foran E, Trotti D (2009). Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid Redox Signal 11: 1587–1602.
23. Guida F, Lattanzi R, Boccella S, Maftei D, Romano R, Marconi V et al. (2015). PC1, a non-peptide PKR1-preferring antagonist, reduces pain behavior and spinal neuronal sensitization in neuropathic mice. Pharmacol Res 91: 36–46.
24. Guo Y, Wang Q, Zhang K, An T, Shi P, Li Z et al. (2012). HO-1 induction in motor cortex and intestinal dysfunction in TDP-43 A315T transgenic mice. Brain Res 1460: 88–95.
25. Habib AA, Mitsumoto H (2011). Emerging drugs for amyotrophic lateral sclerosis. Expert Opin Emerg Drugs 16: 537–558.
26. Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, Frakes A et al. (2011). Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 29: 824–828.
27. Hardiman O, van den Berg LH, Kiernan MC (2011). Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol 7: 639–649.
28. Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S et al. (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucl Acids Res 46: D1091–D1106.
29. Ilieva H, Polymenidou M, Cleveland DW (2009). Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 187: 761–772.
30. Janssens J, Van Broeckhoven C (2013). Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. Hum Mol Genet 22: R77–R87.
31. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.
32. Kim K, Moore DH, Makriyannis A, Abood ME (2006). AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol 542: 100–105.
33. Lagier-Tourenne C, Polymenidou M, Cleveland DW (2010). TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet 19: R46–R64.
34. Lee J, Hyeon SJ, Im H, Ryu H, Kim Y, Ryu H (2016). Astrocytes and microglia as non-cell autonomous players in the pathogenesis of ALS. Exp Neurobiol 25: 233–240.
35. McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189–3193.
36. Moreno-Martet M, Espejo-Porras F, Fernández-Ruiz J, de Lago E (2014). Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex®-like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. CNS Neurosci Ther 20: 809–815.
37. Raman C, McAllister SD, Rizvi G, Patel SG, Moore DH, Abood ME (2004). Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord 5: 33–39.
38. Renton AE, Chiò A, Traynor BJ (2014). State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17: 17–23.
39. Ripps ME, Huntley GW, Hof PR, Morrison JH, Gordon JW (1995). Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 92: 689–693.
40. Rothstein JD (2017). Edaravone: a new drug approved for ALS. Cell 171: 725.
41. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59–62.
42. Schiffer D, Cordera S, Cavalla P, Migheli A (1996). Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci 139 (Suppl): 27–33.
43. Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL (2007). The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 101: 87–98.
44. Tsao W, Jeong YH, Lin S, Ling J, Price DL, Chiang PM et al. (2012). Rodent models of TDP-43: recent advances. Brain Res 1462: 26–39.
45. Van Damme P, Robberecht W, Van Den Bosch L (2017). Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis Model Mech 10: 537–549.
46. Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH (2009). TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A 106: 18809–18814.
47. Weydt P, Hong S, Witting A, Möller T, Stella N, Kliot M (2005). Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph Lateral Scler Other Motor Neuron Disord 6: 182–184.
48. Witting A, Weydt P, Hong S, Kliot M, Möller T, Stella N (2004). Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J Neurochem 89: 1555–1557.
49. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH et al. (2008). Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 11: 251–253.
50. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C et al. (2006). COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 6: 12.